This was the stock's third consecutive day of losses.

This was the stock's second consecutive day of losses.

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $179.53 which represents a decrease of $-0.57 or -0.32% from the prior close of $180.1. The stock opened at $179.63 and touched a low of ...

Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...

CWA Asset Management Group LLC cut its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 13.1% in the 4th quarter, ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger ...

We recently compiled a list of the Top 20 Dividend Stocks of 2024. In this article, we are going to take a look at where ...

We recently compiled a list of the 10 Best Dividend Growth Stocks to Buy and Hold in 2025. In this article, we are going to ...

BofA Securities has recently resumed AbbVie Inc (ABBV) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on December 5, 2024, Daiwa Securities had reduced the ...

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow as in the traditional DCF model, the GuruFocus DCF calculator uses EPS ...